Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as…
Standard pembrolizumab plus lenvatinib remains the best first-line option for advanced kidney cancer, as adding other drugs didn't improve outcomes.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H…
Some people with specific rectal cancers respond completely to immunotherapy alone, potentially avoiding surgery and radiation's significant side effects.
Standard additionConcordance Between Trial Efficacy and Real-World Effectiveness of…
SGLT2 inhibitors show real-world mortality benefits for heart failure that align with clinical trial results, suggesting genuine clinical value.
Standard addition[Efficacy and safety of GLP-1 receptor agonists combined with…
GLP-1 drugs help people who regain weight after bariatric surgery lose an additional 10% body weight on average versus standard care.
Near-term implementable finding[Expert consensus on testosterone supplementation to alleviate…
Emerging evidence suggests testosterone therapy may improve certain aging-related symptoms in men, though clinical application requires careful evaluation.